653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Bispecific T Cell Engager Therapies and Novel Targeting Agents
Watch Session
290 A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) clinically relevant abstract
Ajai Chari, Jesus G. Berdeja, Albert Oriol, et al.
Deepu Madduri, Ashley Rosko, Jason Brayer, et al.
292 Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma clinically relevant abstract
Adam D. Cohen, Simon J Harrison, Amrita Krishnan, et al.
293 Initial Results of a Phase I Study of TNB-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Relapsed/Refractory Multiple Myeloma clinically relevant abstract
Cesar Rodriguez, Anita D'Souza, Nina Shah, et al.
Marc S. Raab, Nicola Giesen, Christof Scheid, et al.
Fredrik Schjesvold, Vincent Ribrag, Paula Rodriguez-Otero, et al.